Searchable abstracts of presentations at key conferences in endocrinology

ea0063p417 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Extreme improvement in metabolic status with remarkable weight loss of 64 kg after adrenalectomy due to Cushing syndrome, and development of rheumatoid arthritis eight months later

Obradovic Angelina , Nemet Tucic Klara

A 48-year - old woman was admitted in september 2015 for Cushing clinical sings obesity, weight was 120 kg, BMI 44,4 kg/m2, arterial hypertension 160/120 mmHg, hyperlipidemia, moon face, purplish abdominal strie, amenorrhoea, marked swelling of bouth lags, more right leg with varices. Because high D dimer and factor VIII there was suspicion of deep venous thrombosis, Doppler of veins was done immediately wich excludes deep vein thrombosis, and as part of preoperativ...

ea0026p496 | Bone/calcium/Vitamin D | ECE2011

Hip and lumbar spine BMD in overweight postmenopausal women

Nemet Klara Tucic , Polovina Snezana , Obradovic Angelina

Obese subjects have lower risk for osteoporosis than normal weight people. Body mass index over 33 kg/m2 is associated with lowest risk for hip fracture in both sexes.Aim: Investigate overweight influence on bone mineral density of hip bone and lumbar spine in overweight postmenopausal women.Material and methods: Postmenopausal women N=100, without co-morbidity, 48–88 years of age, divided in two groups: grou...

ea0020p58 | Thyroid | ECE2009

The influence of thyroxine replacement therapy on bone mineral density in hypothyroid subjects

Polovina Snezana , Nemet Klara Tucic , Pletikosic Ivana , Obradovic Angelina

Recent studies have suggested that subjects receiving thyroxine replacement therapy are in potentially increased risk of osteoporosis. We set out to measure bone mineral densities by ultrasound bone densitometry (UBMD) in three groups: group A of post-menopausal women (N=25) mean age 65 (±14), group B of women in generative period (N=20) mean age 41(±11), and group C (N=18) male mean age 54, receiving thyroxine replacement therapy during two year...

ea0022p558 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Clinically silent pituitary macroadenomas: a clinicopathologic analysis

Djurdjevic Sandra Pekic , Gazibara Milica Skender , Obradovic Angelina , Gacic E Manojlovic , Doknic Mirjana , Miljic Dragana , Djurovic Marina , Stojanovic Marko , Popovic Vera

Background: The so-called silent pituitary adenomas are a subtype of pituitary tumors showing positive immunoreactivity for one or more pituitary hormones, but without any clinical manifestations for oversecretion of these hormones. They are clinically labeled as non-functional pituitary adenomas (NFPA), some of them with particularly aggressive behavior. Rare patients might present with big plurihormonal pituitary tumors which ‘whisper’ hormones (GH or ACTH) and pro...